Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Glenmark Launches Latanoprost Ophthalmic Solution | Contract Pharma

What are you searching for?

Sign in
Breaking News

Glenmark Launches Latanoprost Ophthalmic Solution

The product is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan Ophthalmic Solution, 0.005%.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Glenmark Pharmaceuticals Inc. USA has launched Latanoprost Ophthalmic Solution, a 0.005% (0.05 mg/mL) ophthalmic solution. This product is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan Ophthalmic Solution.

Marc Kikuchi, President & Business Head, North America, expressed excitement about the launch, stating that it marks the fourth ophthalmic product in Glenmark’s portfolio.

“This addition highlights our commitment to meeting market needs and providing quality solutions for our customers,” Kikuchi remarked.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics